IL132634A0 - Allelic polygene diagnosis of reward deficiency syndrome and treatment - Google Patents
Allelic polygene diagnosis of reward deficiency syndrome and treatmentInfo
- Publication number
- IL132634A0 IL132634A0 IL13263498A IL13263498A IL132634A0 IL 132634 A0 IL132634 A0 IL 132634A0 IL 13263498 A IL13263498 A IL 13263498A IL 13263498 A IL13263498 A IL 13263498A IL 132634 A0 IL132634 A0 IL 132634A0
- Authority
- IL
- Israel
- Prior art keywords
- allelic
- treatment
- deficiency syndrome
- reward deficiency
- polygene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4439497P | 1997-04-29 | 1997-04-29 | |
| PCT/US1998/008684 WO1998048785A2 (en) | 1997-04-29 | 1998-04-29 | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL132634A0 true IL132634A0 (en) | 2001-03-19 |
Family
ID=21932148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13263498A IL132634A0 (en) | 1997-04-29 | 1998-04-29 | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0979092A2 (en) |
| JP (1) | JP2002511850A (en) |
| KR (1) | KR20010020422A (en) |
| CN (1) | CN1261801A (en) |
| AU (1) | AU7267798A (en) |
| CA (1) | CA2288990A1 (en) |
| IL (1) | IL132634A0 (en) |
| IS (1) | IS5233A (en) |
| NO (1) | NO995257L (en) |
| WO (1) | WO1998048785A2 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| US6955873B1 (en) * | 2000-08-04 | 2005-10-18 | Kenneth Blum | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors |
| GB9927806D0 (en) | 1999-11-24 | 2000-01-26 | Isis Innovation | Genetic indicators of tobacco consumption |
| DK1347778T3 (en) * | 2000-12-01 | 2006-10-09 | Be Able Llc | behavioral Chemotherapy |
| ITRM20010218A1 (en) * | 2001-04-23 | 2002-10-23 | Sigma Tau Healthscience Spa | COMPOSITION FOR THE PREVENTION OR TREATMENT OF LEARNING DISORDERS IN CHILDREN AFFECTED BY ATTENTION DEFICIT AND HYPERACTIVE |
| US8142800B1 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | Oral high potency clinical anti-craving treatment and method of use |
| US8142799B2 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | High potency clinical anti-craving treatment and method of use |
| JP5265923B2 (en) * | 2005-02-07 | 2013-08-14 | ジーンニュース インコーポレーテッド | Biomarkers for mild osteoarthritis and uses thereof |
| US8572472B2 (en) | 2006-09-28 | 2013-10-29 | Mitsubishi Electric Corporation | Fault detection apparatus, fault detection method, and fault detection program |
| WO2009155585A1 (en) * | 2008-06-21 | 2009-12-23 | Blumy Kenneth | N utragenomics |
| WO2010005303A2 (en) * | 2008-07-07 | 2010-01-14 | Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | New indicators of human longevity and biological ageing rate |
| US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
| WO2011133949A2 (en) * | 2010-04-22 | 2011-10-27 | Kenber, Llc | Genetic risk analysis in reward deficiency syndrome |
| WO2013047912A1 (en) * | 2011-09-30 | 2013-04-04 | 公益財団法人東京都医学総合研究所 | Method for evaluating drug sensitivity and susceptibility to diseases by analyzing gene for protein capable of binding to cyclic-amp-responsive sequence |
| JP2015067581A (en) * | 2013-09-30 | 2015-04-13 | 国立大学法人京都大学 | Probe for multiple resonance |
| US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
| CN103990106A (en) * | 2014-06-11 | 2014-08-20 | 河北医科大学 | Application of cholecystokinin octapeptide in medicine preparation |
| US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
| CN104846015B (en) * | 2015-05-27 | 2018-03-27 | 深圳先进技术研究院 | The composition of GABA serotonergic neurons in special heat nucleus accumbens septi and its application in schizophrenia difference behavior is improved |
| CN109069824B (en) * | 2016-02-02 | 2022-09-16 | 阿莱瓦神经治疗股份有限公司 | Treatment of autoimmune diseases using deep brain stimulation |
| US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
| US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
| CN109316196B (en) * | 2018-12-12 | 2022-07-19 | 上海市精神卫生中心（上海市心理咨询培训中心） | Amphetamine stimulant craving assessment method based on virtual reality and electroencephalogram monitoring |
| CN110507294B (en) * | 2019-08-07 | 2022-02-08 | 北京安龙脉德医学科技有限公司 | First-aid system based on internet information transmission |
| CN110991044B (en) * | 2019-12-03 | 2023-02-24 | 北京机电工程研究所 | Agent modeling-based aircraft system task reliability assessment method |
| CN112862751B (en) * | 2020-12-30 | 2022-05-31 | 电子科技大学 | Automatic diagnosis device for autism |
| CN113332299A (en) * | 2021-05-27 | 2021-09-03 | 广东湛江海洋医药研究院 | Application of salidroside in relieving glucocorticoid-induced osteoporosis |
| KR102434668B1 (en) * | 2022-03-02 | 2022-08-22 | 주식회사 국개대표 | Feed for pets that can improve separation anxiety symptoms and manufacturing thereof |
| CN115830001B (en) * | 2022-12-22 | 2023-09-08 | 抖音视界有限公司 | Intestinal tract image processing method and device, storage medium and electronic equipment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US4761429A (en) * | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
| US5013752A (en) * | 1989-03-10 | 1991-05-07 | Dobbins John P | Prevention and treatment of alcoholism by the use of dietary chromium |
| US5019594A (en) * | 1989-11-28 | 1991-05-28 | Interneuron Pharmaceuticals, Inc. | Method for decreasing appetite |
| US5164384A (en) * | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
| US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
-
1998
- 1998-04-29 AU AU72677/98A patent/AU7267798A/en not_active Abandoned
- 1998-04-29 CN CN98806484A patent/CN1261801A/en active Pending
- 1998-04-29 WO PCT/US1998/008684 patent/WO1998048785A2/en not_active Application Discontinuation
- 1998-04-29 IL IL13263498A patent/IL132634A0/en unknown
- 1998-04-29 EP EP98920019A patent/EP0979092A2/en not_active Withdrawn
- 1998-04-29 JP JP54736498A patent/JP2002511850A/en active Pending
- 1998-04-29 CA CA002288990A patent/CA2288990A1/en not_active Abandoned
- 1998-04-29 KR KR1019997010047A patent/KR20010020422A/en not_active Application Discontinuation
-
1999
- 1999-10-28 IS IS5233A patent/IS5233A/en unknown
- 1999-10-28 NO NO995257A patent/NO995257L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0979092A2 (en) | 2000-02-16 |
| IS5233A (en) | 1999-10-28 |
| NO995257D0 (en) | 1999-10-28 |
| KR20010020422A (en) | 2001-03-15 |
| CA2288990A1 (en) | 1998-11-05 |
| NO995257L (en) | 1999-12-27 |
| WO1998048785A9 (en) | 1999-05-20 |
| CN1261801A (en) | 2000-08-02 |
| WO1998048785A2 (en) | 1998-11-05 |
| AU7267798A (en) | 1998-11-24 |
| JP2002511850A (en) | 2002-04-16 |
| WO1998048785A3 (en) | 1999-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL132634A0 (en) | Allelic polygene diagnosis of reward deficiency syndrome and treatment | |
| ZA9710752B (en) | Absorbent articles having cuffs and topsheet with skin care composition disposed thereon. | |
| DE69529307T2 (en) | Ultrasound diagnosis and treatment system | |
| BR9507984A (en) | Bleaching and oxidation catalyst and bleaching composition | |
| HUP9802662A3 (en) | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | |
| EP1056514A4 (en) | Endoluminal implant with therapeutic and diagnostic capability | |
| DE69836008D1 (en) | COMPOSITION AND TREATMENT AGENT | |
| HUP9904361A3 (en) | Use of isobutylgaba and its derivatives for the treatment of pain | |
| ZA977263B (en) | Treatment of upper airway allergic responses. | |
| AU2981099A (en) | Treatment of compulsive behaviours in man and animals | |
| IL135947A0 (en) | Human blood bacterium | |
| AU2466695A (en) | The use of famotidine and related compounds in the treatment of movement disorders | |
| HUP0003235A3 (en) | Absorbent articles having cuffs with skin care composition disposed thereon | |
| IL120909A0 (en) | Compositions and means for the treatment of burns and other cutaneous traumas | |
| AP9500757A0 (en) | Treatment of disease and conditions associated with macrophage infiltration | |
| PL337577A1 (en) | Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor | |
| ID24065A (en) | TREATMENT OF DIABETES WITH TIOZOLIDINDINONE AND SULFONILUREA | |
| ATE366577T1 (en) | TREATMENT OF DIABETES WITH THIAZOLIDINDIONE AND SULPHONYLUREA | |
| DE69635851D1 (en) | Non-antigenic stabilizer and physiological active agent | |
| ZA97902B (en) | Biologically active ureido derivatives useful in the treatment of multiple sclerosis. | |
| ZA989514B (en) | Treatment of diabetic retinopathy | |
| IL121656A0 (en) | Diagnosis prevention and treatment of diabetes | |
| GB9411065D0 (en) | Enzymatic biosensor and its use | |
| GB9423702D0 (en) | Diagnosis and treatment of tumours | |
| GB9618290D0 (en) | Treatment of diabetes |